Mesalazina Alfasigma (Mesalazine)

Mesalazine acts locally in the gut to inhibit cyclooxygenase and lipoxygenase enzymes, decreasing the production of prostaglandins and leukotrienes. It also modulates cytokine release, which together lower inflammation and promote healing of the intestinal lining.

The appropriate dose of Mesalazina Alfasigma is determined by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. Dosage regimens can vary, and patients should follow the prescriber’s instructions exactly.

Safety data for mesalazine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To request Mesalazina Alfasigma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mesalazina Alfasigma contains mesalazine, the same active moiety found in other 5‑ASA products such as sulfasalazine and balsalazide. While efficacy is comparable, formulation differences can affect tolerability, dosing frequency and drug‑interaction profiles, allowing clinicians to tailor therapy to individual patient needs.

Store Mesalazina Alfasigma at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. Do not refrigerate or freeze unless the label specifically advises otherwise.

Mesalazina Alfasigma is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the prescriber’s guidance to minimise gastrointestinal discomfort.

Serious adverse events include severe allergic reactions such as anaphylaxis, interstitial nephritis, hepatic dysfunction, blood dyscrasias like neutropenia, and pancreatitis. Patients should seek immediate medical attention if they experience symptoms such as rash, swelling, fever, jaundice, or unusual bleeding.

Mesalazina Alfasigma should be avoided in individuals with known hypersensitivity to mesalazine or any 5‑ASA component, those with severe renal or hepatic impairment, and patients who have experienced serious adverse reactions to similar agents. A healthcare professional must evaluate suitability before initiating therapy.